source
- FDA proposes new framework prioritizing consistency over flexibility for rare disease drug reviewsThe FDA announced a shift in its approach to evaluating rare disease therapies, emphasizing a more uniform assessment process. Agency officials explained that the flexibility shown over the summer…
- Verastem’s experimental KRAS drug shows early promise in small study, shares jump 18%Verastem Oncology announced early data from a small study of its experimental drug VS-7375, which targets the KRAS G12D mutation. The study enrolled patients with metastatic pancreatic ductal aden…